Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AGILE Platform Trial for COVID-19 Treatments
NCT04746183Phase 2Recruiting
- Sponsor
- University of Liverpool
- Start
- Jul 2020
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies, RNA-Targeting Small Molecules, Metabolically Activated Prodrugs
- Countries
- 2
01
Overview
A Phase 2 trial of molnupiravir, nitazoxanide, beludavimab, sotrovimab, favipiravir in coronavirus disease 2019 (COVID-19), sponsored by University of Liverpool. Started Jul 2020; status: recruiting.
02
Drugs
molnupiravirnitazoxanidebeludavimabsotrovimabfavipiravir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04746183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04746183.